Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Market Cap & Net Worth: Immunovia AB (0G8X)
Immunovia AB (LSE:0G8X) has a market capitalization of $281.01K (Skr3.15 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #38514 globally and #538 in its home market, demonstrating a -16.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovia AB's stock price Skr0.16 by its total outstanding shares 19531400 (19.53 Million).
Immunovia AB Market Cap History: 2026 to 2026
Immunovia AB's market capitalization history from 2026 to 2026. Data shows growth from $281.01K to $281.01K (0.00% CAGR).
Immunovia AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovia AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0G8X by Market Capitalization
Companies near Immunovia AB in the global market cap rankings as of March 18, 2026.
Key companies related to Immunovia AB by market ranking:
- RENASANT (BE:RN6): Ranked #38505 globally with a market cap of $298.32K USD ( €290.62K EUR).
- Falcon Inv. Falcon DK Aktier (CO:FIIFDA): Ranked #38506 globally with a market cap of $298.24K USD ( Dkr2.17 Million DKK).
- POLYONE (MU:PY9): Ranked #38515 globally with a market cap of $296.96K USD ( €289.30K EUR).
- Saluda Medical Inc (AU:SLD): Ranked #38516 globally with a market cap of $296.82K USD ( AU$479.37K AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #38505 | RENASANT | BE:RN6 | $298.32K | €30.40 |
| #38506 | Falcon Inv. Falcon DK Aktier | CO:FIIFDA | $298.24K | Dkr226.60 |
| #38515 | POLYONE | MU:PY9 | $296.96K | €30.79 |
| #38516 | Saluda Medical Inc | AU:SLD | $296.82K | AU$0.85 |
Immunovia AB Historical Marketcap From 2026 to 2026
Between 2026 and today, Immunovia AB's market cap moved from $281.01K to $ 281.01K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr281.01K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Immunovia AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $281.01K USD |
| MoneyControl | $281.01K USD |
| MarketWatch | $281.01K USD |
| marketcap.company | $281.01K USD |
| Reuters | $281.01K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.